OR WAIT null SECS
Aragen’s new 12,000 ft² facility will include various dosage form capabilities, including oral solids, liquids, topicals, and films.
Aragen Life Sciences, an Indian contract research development and manufacturing organization, announced on Oct. 20, 2022 that it would operationalize its formulation manufacturing facility in Hyderabad, India by 2023. The new 12,000 ft² facility will include various dosage form capabilities for oral solids, liquids, topicals, films, as well as manufacturing technologies for granulation, film coating, spray drying, and tableting, and expansion plans are in place to add nano milling and hot melt extrusion capabilities.
According to a company press release, these new capabilities are designed to enhance the company’s early-stage development offerings by adding additional flexibility in terms of multiple dosage forms. The facility will also feature process technologies and flexible batch sizes from 1000 to 100,000 units.
“Aragen is investing in expanding capacities, extending capabilities and widening its geographic footprint to meet the needs of the global biopharma industry,” said Manni Kantipudi, CEO, Aragen Life Sciences, in the release. “We understand that our customers rely on our expertise, track record, and solution offerings. With this facility, we will consolidate our drug product development solution offerings and strengthen our position as a one-stop shop for all their needs – transforming ideas into solutions for better health."
“The formulation manufacturing facility in Hyderabad is a significant development for us,” said Ramesh Subramanian, chief commercial officer, Aragen Life Sciences, in the release. “The new capacity will allow us to address the increasing interest from our customers for integrated development solutions. It also fits in well with our stated vision of becoming the ‘R&D partner of choice’ for our customers.”
Source: Aragen Life Sciences